Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SEASPINE HOLDINGS CORPORATION

(SPNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

SeaSpine to Participate in the Cantor Virtual Global Healthcare Conference

09/22/2021 | 04:06pm EDT

CARLSBAD, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the Company will present at the Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021, beginning at 8:00 am ET.

A live and archived webcast of the event will be available from the Investor Relations page of the Company's website at investor.seaspine.com.

About SeaSpine
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development, and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions, as well as a market leading surgical navigation system, to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic, and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in orthobiologic sciences, as well as spinal implants, software and advanced optics product development, allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.

Investor Relations Contact
Leigh Salvo
(415) 937-5402
ir@seaspine.com


Primary Logo


ę GlobeNewswire 2021
All news about SEASPINE HOLDINGS CORPORATION
10/11SEASPINE : Launches NorthStar OCT Posterior Cervical Fixation System
MT
10/11SEASPINE : Announces Full Commercial Launch of The NorthStar OCT Posterior Cervical Fixati..
GL
10/11SeaSpine Announces Full Commercial Launch of The NorthStar OCT Posterior Cervical Fixat..
CI
10/06SEASPINE : Announces First Cases of 7D Surgical Percutaneous Spine Moduleáfor Minimally In..
GL
10/06SeaSpine Announces First Cases of 7D Surgical Percutaneous Spine Moduleáfor Minimally I..
CI
10/04SEASPINE : Says Vizient Awards Innovative Technology Contract for 7D FLASH Surgical Naviga..
MT
10/04SEASPINE : reg; Receives Innovative Technology Contract from Vizient for its 7D FLASH&trad..
AQ
10/04SeaSpine Holdings Corporation Receives Innovative Technology Contract from Vizient for ..
CI
09/28SEASPINE : Receives CE Mark Certification for 7D Surgical Cranial and Percutaneous Spine M..
MT
09/27SEASPINE : Announces CE Mark Certification of 7D Surgical Cranial Module and Percutaneous ..
GL
More news
Analyst Recommendations on SEASPINE HOLDINGS CORPORATION
More recommendations
Financials (USD)
Sales 2021 197 M - -
Net income 2021 -34,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -13,9x
Yield 2021 -
Capitalization 543 M 543 M -
Capi. / Sales 2021 2,76x
Capi. / Sales 2022 2,45x
Nbr of Employees 421
Free-Float 84,7%
Chart SEASPINE HOLDINGS CORPORATION
Duration : Period :
SeaSpine Holdings Corporation Technical Analysis Chart | SPNE | US81255T1088 | MarketScreener
Technical analysis trends SEASPINE HOLDINGS CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 14,92 $
Average target price 27,61 $
Spread / Average Target 85,0%
EPS Revisions
Managers and Directors
Keith C. Valentine President, Chief Executive Officer & Director
John J. Bostjancic Chief Financial Officer, Treasurer & Senior VP
Kirtley C. Stephenson Non-Executive Chairman
Chris Shen VP-Information Technology & Customer Experience
Frank Vizesi Vice President-Clinical Affairs
Sector and Competitors